Sign In
Buy SRPT
$16.24
-0.0100 (-0.0615%)
At Close: Jun 03, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Jan. 26, 2026, at 8:30 am Easte
2 Beaten-Down Stocks That Could Sink Even More in 2026
10:30pm, Wednesday, 21'st Jan 2026
Sarepta Therapeutics' drug safety issues are overshadowing its innovative platform. Teladoc Health's financial results continue to worsen, and the stock looks unlikely to recover.
Sarepta Therapeutics, Inc. $SRPT Stock Holdings Boosted by State of Alaska Department of Revenue
05:26am, Monday, 19'th Jan 2026
State of Alaska Department of Revenue increased its position in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 343.7% during the third quarter, according to the company in its most recent 13F filing wit
Sarepta Therapeutics: Is Elevidys A Bust?
09:25am, Friday, 16'th Jan 2026
Sarepta Therapeutics remains highly volatile as ELEVIDYS sales drive sentiment, with Q4 revenue missing expectations and safety concerns lingering. Despite fading ELEVIDYS sales, SRPT management reite
Market Today: Banks, Big Tech, Biopharma and Energy Move on Policy and Deals
05:34pm, Monday, 12'th Jan 2026
Guru Stock PicksJerome Dodson has made the following transactions:Reduce in ORLY by 3%Sold out in BLDRAdd in NTRA by 2.49%New position in INSMTweedy Browne Inte
Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:36pm, Monday, 12'th Jan 2026
Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
11:58am, Monday, 12'th Jan 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 ne
Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty
09:30am, Monday, 12'th Jan 2026
San Diego, California--(Newsfile Corp. - January 12, 2026) - Shareholder rights law firm Johnson Fistel, PLLP is investigating potential shareholder derivative claims on behalf of Sarepta Therapeutics
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of “Hold” from Analysts
01:24am, Sunday, 11'th Jan 2026
Shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT - Get Free Report) have been assigned an average rating of "Hold" from the thirty brokerages that are currently covering the stock, Marketbeat Rating
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease
08:30am, Wednesday, 07'th Jan 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the submission of its clinical trial applicatio
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
08:30am, Monday, 05'th Jan 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 44th
Sarepta Therapeutics, Inc. $SRPT Shares Acquired by Cwm LLC
03:10am, Monday, 05'th Jan 2026
Cwm LLC lifted its holdings in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 4,033.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The in
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:20pm, Wednesday, 31'st Dec 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Dec. 31, 2025 that were previously app
Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests
06:48am, Wednesday, 17'th Dec 2025
Sarepta Therapeutics is upgraded to a buy following HHS's addition of Duchenne muscular dystrophy to the newborn screening panel. Earlier DMD detection aligns perfectly with SRPT's preventative therap
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of “Hold” by Brokerages
01:43am, Wednesday, 17'th Dec 2025
Shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT - Get Free Report) have earned an average rating of "Hold" from the thirty brokerages that are covering the stock, Marketbeat Ratings reports. Six eq
